E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers O > Headlines for OncoGenex Pharmaceuticals, Inc. > News item
Published on 6/18/2013 in the Prospect News PIPE Daily.

OncoGenex arranges $25 million at-the-market issuance sales agreement

Offering will be conducted by agent MLV, company reports in 8-K filing

By Devika Patel

Knoxville, Tenn., June 18 - OncoGenex Pharmaceuticals, Inc. negotiated a $25 million at-the-market issuance sales agreement with MLV & Co. LLC on June 18, according to an 8-K filed Tuesday with the Securities and Exchange Commission.

The agent will be paid a 3% commission.

OncoGenex Pharmaceuticals, based in Bothell, Wash., is a biopharmaceutical company engaged in the development and commercialization of cancer therapies.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.